Short answer
Nurix Therapeutics, Inc. (NRIX) filed its Q1 2026 10-Q quarterly report on Apr 8, 2026 for the quarter ended Feb 28, 2026. Quarterly revenue was $6M (down 66.1% year over year) with net income of −$87M.
Q1 2026 key financials · XBRL
- Revenue
- $6M
- −66.1% YoY
- Net income
- −$87M
- −54.7% YoY
- Operating margin
- -1479.4%
- EPS (diluted)
- −$0.79
- −17.9% YoY
Source: XBRL data from the Nurix Therapeutics, Inc. (NRIX) Q1 2026 10-Q on SEC EDGAR. USD.
Nurix Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material-change statement provided; carried-forward financial risk includes $540.7 million liquidity supporting operations through at least 12 months
- Clinical-development risk: lead candidates remain early-stage, with bexobrutideg in Phase 1 and Phase 2 and zelebrudomide and NX-1607 in Phase 1
- Regulatory risk: targeted protein degradation has no approved therapeutics in the United States or Europe
- Operational risk: clinical-trial delays from inadequate drug supply or quality could postpone development
- Financial risk: $87.2 million quarterly net loss and $1.1 billion accumulated deficit underscore ongoing funding needs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nurix Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.